IMRX Immuneering
- 1.470
- 0.0000.00%
- 1.530
- +0.060+4.08%
Immuneering News
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment
USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage...
Buy Rating Affirmed for Immuneering With $8 Price Target Amidst Promising Pipeline and Upcoming Data Events
Oppenheimer Keeps Their Buy Rating on Immuneering (IMRX)
Immuneering Reports Q1 Results
Immuneering Price Target Maintained With a $15.00/Share by Needham
Immuneering Price Target Maintained With a $15.00/Share by Needham
Buy Rating Maintained for Immuneering Amid Promising Clinical Pipeline Developments
Immuneering Q1 EPS $(0.49) Misses $(0.46) Estimate
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.46) by 6.52 percent. This is a 3.92 percent increase over losses of $(0.51)
Immuneering | 10-Q: Quarterly report
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
Preclinical Data Presented at AACR Demonstrating that IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models.
Buy Rating Affirmed: Immuneering's Lead Asset IMM-1-104 Shows Promise Despite Market Skepticism
Needham: Reiterates the Immuneering (IMRX.US) rating, adjusted from buy to buy, with a target price of $15.00.
Needham: Reiterates the Immuneering (IMRX.US) rating, adjusted from buy to buy, with a target price of $15.00.
Needham Reiterates Buy on Immuneering, Maintains $15 Price Target
Needham analyst Ami Fadia reiterates Immuneering with a Buy and maintains $15 price target.
Analysts' Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)
Immuneering Presented Preclinical Data At AACR Annual Meeting For Ongoing Phase 2a Clinical Trial Of IMM-1-104 In RAS-Mutated Advanced Or Metastatic Solid Tumors
Globe Newswire- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor
IMM-1-104 Is Synergistic With Chemotherapy in Pancreatic Cancer Models
CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting, which the company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors.
Immuneering(IMRX.US) 10% Shareholder Sells US$1.16 Million in Common Stock
$Immuneering(IMRX.US)$ 10% Shareholder Cormorant Asset Management, LP sold 400K shares of Common Stock on Apr 1, 2024 at an average price of $2.9 for a total value of $1.16 million. This transaction i
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
PDF Version CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF
Immuneering Is Maintained at Buy by Mizuho
Immuneering Is Maintained at Buy by Mizuho
Immuneering Price Target Cut to $8.00/Share From $20.00 by Mizuho
Immuneering Price Target Cut to $8.00/Share From $20.00 by Mizuho
Immuneering Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 190.91% Mizuho $20 → $8 Maintains Buy 03/15/2024 9.09% Jefferies $16 → $3 Downgrades Buy → Hold
Analysis
Price Target
No Data
